In “My Own Country,” a 1994 memoir, Dr. Abraham Verghese, an infectious disease physician, recounts the story of a young man ...

Investigators from Duke University hypothesized that hirudin-like protease inhibitors could be generated by linking exosite-binding aptamers with small-molecule active site inhibitors, thus generating ...

To access the webcast and subsequent archived recording of the presentation, please visit the “Presentations” section of the KALA website at About KALA BIO, Inc. KALA is a clinical-stage ...

Korro Bio has secured approvals in Australia to commence the Phase I/IIa trial of KRRO-110, aimed at treating AATD.

Analysts are estimating that Enanta Pharma will report an earnings per share (EPS) of $-1.16. The announcement from Enanta Pharma is eagerly anticipated, with investors seeking news of surpassing ...

Laboratory of Chemical Biology, Department of Cellular and Molecular Medicine, KU Leuven − University of Leuven, Herestraat 49 box 901b, 3000 Leuven, Belgium ...

The natural anticoagulant hirudin achieves potent activity by inhibiting both thrombin’s exosite and active site. We hypothesize that hirudin-like protease inhibitors can be generated de novo by ...

Two additional M pro inhibitors, Ensitrelvir (ETV ... "Assessing the Inhibition Efficacy of Clinical Drugs Against the Main Proteases of SARS-CoV-2 Variants and Other Coronaviruses," provides ...

Patients with cancer who receive immune checkpoint inhibitors (ICIs) have more than twice the risk for developing psoriasis compared with those who receive other treatments. Researchers conducted ...

A critical player in the virus's life cycle is the main protease (M pro), also known ... structures and binding modes of four M pro inhibitors. Among these, ETV is the only non-covalent inhibitor ...

Objective To investigate the association between sodium-glucose cotransporter-2 (SGLT-2) inhibitor use and risk of all cause mortality among patients with heart failure with reduced ejection fraction.